Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026

DURHAM, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that it will report its financial results for the second fiscal quarter ended September 30, 2026 on Monday, November 9, 2026 before the market opens. Roivant Sciences Ltd. (Nasdaq: ROIV), Immunovant's majority stockholder, will host a live conference call and webcast at 8:00 a.m. ET that same day, which will include a business update for Immunovant.

GlobeNewsWire • Oct 21, 2026

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.

PRNewsWire • Oct 12, 2026

IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $IMVT--IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law.

Business Wire • Oct 11, 2026

Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)

Immunovant stock fell roughly 6% to a more-than-three-month low on September 23, 2026 after the IMVT-1402 cutaneous lupus study missed its primary endpoint. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of IMVT investors who lost money.

PRNewsWire • Sep 25, 2026

IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down

Immunovant's IMVT-1402 misses its primary CLE goal, prompting the company to halt the program despite positive trends and a favorable safety profile.

Zacks Investment Research • Sep 24, 2026

Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12 Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved clinical outcomes, but the study did not meet Immunovant's internal bar to continue development of IMVT-1402 in CLE IMVT-1402 demonstrated a favorable safety and tolerability profile, consistent with prior studies All other clinical development timelines remain on track DURHAM, N.C., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced topline results from Period 1 of its proof-of-concept trial evaluating IMVT-1402 (imeroprubart) for the treatment of cutaneous lupus erythematosus (CLE).

GlobeNewsWire • Sep 23, 2026

Immunovant Q1 Earnings Call Highlights

Roivant said its first quarter was relatively quiet operationally but positioned the company for a more active second half of 2026, with a potential launch of brepocitinib in dermatomyositis, multiple clinical readouts and further updates from Immunovant NASDAQ: IMVT.

MarketBeat • Aug 6, 2026

Immunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcript

Immunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcript

Seeking Alpha • Aug 6, 2026

Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress

IMVT posts a wider quarterly loss as R&D spending rises, but its cash runway supports IMVT-1402 through a planned Graves' disease commercial launch.

Zacks Investment Research • Aug 6, 2026

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves' disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat rheumatoid arthritis (D2T RA), Sjögren's disease (SjD) and cutaneous lupus erythematosus (CLE) Current cash balance provides runway to the potential launch of IMVT-1402 in GD Roivant will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026 DURHAM, N.C.

GlobeNewsWire • Aug 6, 2026